Zacks Research Issues Positive Outlook for FOLD Earnings
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Analysts at Zacks Research lifted their Q1 2026 EPS estimates for Amicus Therapeutics in a research report issued on Tuesday, April 1st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their prior […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Analysts at Zacks Research lifted their Q1 2026 EPS estimates for Amicus Therapeutics in a research report issued on Tuesday, April 1st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their prior […]
